Asymmetric hydroalkoxylation
of alkenes constitutes a redox-neutral
and 100% atom-economical strategy toward enantioenriched oxygenated
building blocks from readily available starting materials. Despite
their great potential, catalytic enantioselective additions of alcohols
across a C–C multiple bond are particularly underdeveloped,
especially compared to other hydrofunctionalization methods such as
hydroamination. However, driven by some recent innovations, e.g.,
asymmetric MHAT methods, asymmetric photocatalytic methods, and the
development of extremely strong chiral Brønsted acids, there
has been a gratifying surge of reports in this burgeoning field. The
goal of this review is to survey the growing landscape of asymmetric
hydroalkoxylation by highlighting exciting new advances, deconstructing
mechanistic underpinnings, and drawing insight from related asymmetric
hydroacyloxylation and hydration. A deep appreciation of the underlying
principles informs an understanding of the various selectivity parameters
and activation modes in the realm of asymmetric alkene hydrofunctionalization
while simultaneously evoking the outstanding challenges to the field
moving forward. Overall, we aim to lay a foundation for cross-fertilization
among various catalytic fields and spur further innovation in asymmetric
hydroalkoxylations of C–C multiple bonds.
We report a Zn-ProPhenol catalyzed asymmetric Mannich reaction between butenolides and polyfluorinated alkynyl ketimines to obtain vinylogous products featuring two contiguous tetrasubstituted stereogenic centers. Notably, this is the first successful use of ketimines in the ProPhenol Mannich process, and the reaction offers a new approach for the preparation of pharmaceutically relevant products possessing trifluoromethylated tetrasubstituted alkylamines. The reaction can be performed on large scale with reduced catalyst loading without impacting its efficiency. Moreover, the acetylene moiety can be further elaborated using various methods.
Tetrahydroisoquinoline (THIQ) alkaloids constitute a
large and
diverse class of bioactive natural products, with the parent compounds
and related downstream biosynthetic secondary metabolites spanning
thousands of isolated structures. Chemoenzymatic synthetic approaches
toward the relevant THIQs rely on Pictet–Spenglerases such
as norcoclaurine synthase (NCS), the scope of which is strictly limited
to dopamine-related phenolic substrates. To overcome these limitations
in the context of chemical synthesis, we herein report asymmetric
Pictet–Spengler reactions of
N
-carbamoyl-β-arylethylamines
with diverse aldehydes toward enantioenriched THIQs. The obtained
products proved to be competent intermediates in the synthesis of
THIQ, aporphine, tetrahydroberberine, morphinan, and androcymbine
natural products. Novel catalyst design with regard to the stabilization
of cationic intermediates was crucial to accomplish high reactivity
while simultaneously achieving unprecedented stereoselectivity for
the reaction of biologically relevant substrates.
We report a Zn‐ProPhenol catalyzed asymmetric Mannich reaction between butenolides and polyfluorinated alkynyl ketimines to obtain vinylogous products featuring two contiguous tetrasubstituted stereogenic centers. Notably, this is the first successful use of ketimines in the ProPhenol Mannich process, and the reaction offers a new approach for the preparation of pharmaceutically relevant products possessing trifluoromethylated tetrasubstituted alkylamines. The reaction can be performed on large scale with reduced catalyst loading without impacting its efficiency. Moreover, the acetylene moiety can be further elaborated using various methods.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.